Proteolysis targeting chimera therapy- JD Biosceinces
Alternative Names: GM-PROTAC; GM-PROTAC - JD BiosciencesLatest Information Update: 05 Oct 2023
At a glance
- Originator JD BIOSCIENCE
- Class Antineoplastics; Small molecules
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Research Cancer
Most Recent Events
- 06 Sep 2023 Research program: proteolysis targeting chimera therapeutics - JD Biosceinces is available for licensing as of 05 Sep 2023. http://jdbiosci.com/sub_pipeline.php
- 05 Sep 2023 Early research in Cancer in South Korea prior to September 2023 (unspecified route) (JD Biosciences website, September 2023)